FridayOct 03, 2025 10:00 am

Why Health Insurance Credits Led to the Federal Government Shutdown

Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open and on Wednesday, a shutdown commenced. At the core of the disagreement between GOP lawmakers and their Democratic Party counterparts are the health care tax credits in the Affordable Care Act due to expire at the end of this year and which the Big Beautiful Bill’s provisions don’t include an extension to these tax credits.  A lot has been said about the cuts to Medicare and Medicaid under that law, and the refusal to renew those ACA tax credits only piles to the hardship that…

Continue Reading

ThursdayOct 02, 2025 10:00 am

Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm

In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare bacteria’, a category of bacteria characterized by three deadly attributes; resistance to all or almost all antibiotics, high mortality levels, and their ability to spread antibiotic resistance to other types of bacteria. From this triple threat of these microbes, one can understand why they are described as ‘nightmare bacteria.’ Data shows that cases of these bacteria are increasing at an alarming rate in the U.S.  Available statistics indicate that there has been a nearly 70% spike in incidences of nightmare bacteria in the years 2019-2023.…

Continue Reading

WednesdayOct 01, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003 Sapu003 uses Sapu Nano’s Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic…

Continue Reading

WednesdayOct 01, 2025 9:00 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection. This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies. Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients. Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company…

Continue Reading

TuesdaySep 30, 2025 10:30 am

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and…

Continue Reading

TuesdaySep 30, 2025 10:00 am

Scorpion Venom Shows Promise in Brain Tumor Treatment

The sight of a scorpion moving towards you with its stinger raised can send a chill down the spine of the bravest among us. If you watched Fear Factor, you saw how terrified the contestants were to come face to face with these creatures. While scorpions have been portrayed as the stuff of nightmares, scientists have found that they can be useful in the fight against brain cancer.  The study, which was conducted by City of Hope, a consortium of research centers in different cities around America focused on studying cancer, suggests that scorpion venom can help to guide our…

Continue Reading

MondaySep 29, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions. The company’s current study aims to further assess safety and biological activity of SGX302, as well as generate additional data to guide larger studies. SGX302 has already demonstrated positive results in a phase 1/2 pilot study. Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing…

Continue Reading

FridaySep 26, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today

CMS proposal keeps CT radiation quality measure voluntary, highlighting ongoing debate around dose safety and image quality Izotropic’s IzoView breast CT system engineered to deliver low-dose, high-resolution 3D imaging, aligning with future regulatory and clinical priorities Company launches new FAQ page to enhance transparency for investors, clinicians, and decision-makers In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements,…

Continue Reading

FridaySep 26, 2025 10:00 am

Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis

Groundbreaking research presented at the ECTRIMS 2025 conference held in Barcelona, Spain provides new insights into the ways in which menopause impacts the health implications and clinical manifestations in women who have multiple sclerosis. This study shows that changes in hormones influence the initial symptoms experienced by women with MS and also play a role in the comorbidities suffered by the affected individuals.  It has been known that MS disproportionately impacts women and the progression of the disease is influenced by the biological variables of the different sexes. However, the role that menopause plays in people with this disease hasn’t…

Continue Reading

ThursdaySep 25, 2025 9:00 am

Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer

A recently published study by a team at the University of Chicago suggests that a carotenoid called zeaxanthin, naturally occurring in plants like kale, spinach and orange peppers, and well known for its benefits in eye health, could also play a role in supercharging the immune system during the fight against cancer. The research, which appeared in Cell Reports Medicine, indicates that this over-the-counter supplement that is not only affordable but also easily accessible may boost the efficacy of cancer immunotherapies. The study’s senior author, Jing Chen, PhD, explains that the team was surprised when they found that the nutrient…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000